Avricore to Present at Emerging Growth Conference on Oct. 26, 2022

Avricore to Present at Emerging Growth Conference on Oct. 26, 2022

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to present at the Emerging Growth Conference on October 26 th .

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Hector Bremner in real time on the Company's current activities. After a short presentation, the floor will be subsequently opened for questions, where Mr. Bremner will do his best to get through as many of them as possible.

Call Details:

October 26, 2022 @ 11:30am PT / 2:30pm ET
Please register here to ensure you can attend the conference and receive any updates that are released: https://goto.webcasts.com/starthere.jsp?ei=1575084&tp_key=b452034330&sti=avcrf

*If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on www.EmergingGrowth.com and we will also release a link to that after the event .

Agenda:

The 30-minute call agenda will be as follows:

15Min: Overview Presentation
15Min: Q&A

We're looking forward to seeing you there, please review our most recent investor presentation here: www.avricore.com

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

HealthTab™ Market Fast Facts

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 ( Source )
  • Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source )
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source )
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed ( Source )
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact :

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
The Conversation (0)
Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.

"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a reseller agreement between HealthTab™ Inc. and Abbott Rapid Dx UK & Ireland.

This agreement provides a foundation for HealthTab to purchase and distribute the Afinion™ 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased that HealthTab, the Company's leading pharmacy-based platform for testing and health data management, has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

"In the wake of the pandemic, it's clear that the community pharmacy needs to play a bigger role in delivering more access to healthcare services, especially chronic disease screening and management," said Hector Bremner, CEO of Avricore Health. "We are honoured to have been selected for this important project and look forward to working with pharmacist as they support patients with this vital service."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Arrow pointing down against red background.

Tech 5: Recession Fears Kick Panic Selling into Overdrive, Tech Selloff Ensues

The stock market experienced a turbulent week influenced by concerns over US economic data. Cryptocurrencies also experienced significant losses before recovering toward the end of the week.

Meanwhile, a long-awaited ruling could have massive implications for the tech sector, and a California-based chip stock became the most recent to fall short of steep expectations.

Stay informed on the latest developments in the tech world with the Investing News Network's round-up.

Keep reading...Show less
Aether Global Innovations Corp. Announces Resignation of its Chief Financial Officer

Aether Global Innovations Corp. Announces Resignation of its Chief Financial Officer

(TheNewswire)

Aether Global Innovations Corp.

Vancouver, B.C. August 9, 2024 Aether Global Innovations Corp. ( CSE: AETH ) ( OTCQB: AETHF ) ( Frankfurt: 4XA WKN# A2N8RH) (" Aether Global" " AETH ", or the " Company "), a drone management and automation company announced today the resignation of its Chief Financial Officer, Miss Karen Mae Parrin.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Gold Intel logo on black background.

Intel Facing Shareholder Lawsuit After Disappointing Q2 Results

Intel (NASDAQ:INTC) is facing legal action from its shareholders following a significant drop in its share price that was triggered by factors such as poor results, job cuts and the suspension of dividends.

The lawsuit, filed in a San Francisco federal court on Wednesday (August 7), alleges that Intel fraudulently concealed business challenges that ultimately led to disappointing Q2 results and a sharp decline in its market value.

The lead plaintiff, the Construction Laborers Pension Trust of Greater St. Louis, claims Intel and its executives made materially false or misleading statements about the company’s manufacturing capabilities and business performance.

Keep reading...Show less
Apple, Amazon and Microsoft logos against tall buildings.

​Tech 5: Tech Stocks Volatile as Recession Fears Rise, Trump Promises Crypto Reserve

A week of earnings reports and troubling economic data sent tech stocks on a wild ride this week.

Meanwhile, US President Donald Trump made an appearance at a Bitcoin event in Nashville, Tennessee, promising a friendly environment for crypto if he is elected in November — including a strategic Bitcoin reserve.

Additionally, the competitive chip stock landscape is about to get a new competitor.

Keep reading...Show less
Apple reports third quarter results

Apple reports third quarter results

June quarter records for Revenue and EPS

Services revenue reaches new all-time high

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
E-Power Samples 34.8 % Cg in Newly Discovered Graphitic Rock Trends

E-Power Samples 34.8 % Cg in Newly Discovered Graphitic Rock Trends

E-Power Resources Inc. (CSE: EPR) ("E-Power" or the "Company") is pleased to report results from the first phase of the 2024 exploration program on the Company's flagship Tetepisca flake graphite property located in the North Shore region of Québec. Highlights include the discovery of graphite bearing metamorphic rocks along three conductor trends which include a high of 31 % Cg (Graphite Carbon) from an outcrop grab sample and a sample of proximal float rock which returned a value of 24.8% Cg from a 4th conductor target area.

James Cross, President and CEO of E-Power commented:"We are completing metallurgical and mineralogical chacterization studies on our Tetepisca Property to determine product quality and applicability to end users. At the same time, we are conducting a propecting program focussed on the northern end of our property. The prospecting is to evaluate our large land position in an effort to demonstrate large tonnage potential in multiple target areas. The results of the prospecting completed to date, including high grade grab samples, are very enouraging. We look forward to the metallurgical test work results as well as continued success in the field program through the 2024 exploration campaign."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×